Edesa Biotech (EDSA) Current Deferred Revenue (2014 - 2019)

Edesa Biotech (EDSA) posted Current Deferred Revenue of $80000.0 for Q1 2019, little changed sequentially from $80000.0 in Q4 2018.

Edesa Biotech (EDSA) Current Deferred Revenue (2014 - 2019) Analysis & Trends

Edesa Biotech has reported Current Deferred Revenue for 5 years, with the latest figure at $80000.0 in Q1 2019.

Quarterly Current Deferred Revenue changed N/A year-over-year to $80000.0 in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $80000.0 (changed N/A YoY) and the FY2015 annual result came in at $173333.0, changed N/A from the prior year.
Current Deferred Revenue held at $80000.0 in Q1 2019 per EDSA's latest filing, from $80000.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $173333.0 in Q2 2015 and troughed at $80000.0 in Q4 2018.
A 4-year average of $142222.0 and a median of $173333.0 in 2015 frame the typical range for Current Deferred Revenue.
The widest YoY moves for Current Deferred Revenue: up 0.0% in 2016, down 0.0% in 2016.
Over 4 years, Current Deferred Revenue stood at $173333.0 in 2015, then changed by 0.0% to $173333.0 in 2016, then plunged by 53.85% to $80000.0 in 2018, then changed by 0.0% to $80000.0 in 2019.
According to Business Quant data, Current Deferred Revenue over the past three periods registered $80000.0, $80000.0, and $173333.0 for Q1 2019, Q4 2018, and Q2 2016 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Edesa Biotech	40.44 Mn	40.44 Mn	-

Download Data